In the face of the depressed market, A-share company Getein Biotech Inc(603387) decisively "copy the bottom" and wants to directly win a Hong Kong stock company
On April 9, the manufacturer of covid-19 antigen detection reagent Getein Biotech Inc(603387) announced that it planned to hold the in vitro diagnostic product dealer and service provider star medical listed in Hong Kong stock market. Hong Kong stock company Star Medical also disclosed this matter.
On April 11, Getein Biotech Inc(603387) share price rose by nearly 8% at one time, and superstar medical holdings listed in Hong Kong stocks rose by 7.55%. As of midday closing, the share prices of both companies had fallen.
cross market subscription
intends to hold no less than 30%
A-Shares are often subscribed for by Hong Kong stock companies, but the operation of obtaining control after subscription is rare
Getein Biotech Inc(603387) announced that it plans to subscribe for the newly issued shares of superstar medical Holdings Co., Ltd. in cash. After the subscription is completed, Getein Biotech Inc(603387) will hold no less than 30% of the total shares of superstar medical after the issuance of new shares, and will become the controlling shareholder of superstar medical. Superstar medical will become the consolidated subsidiary of Getein Biotech Inc(603387) .
Statistics show that superstar medical is one of the largest distributors and service providers of in vitro diagnostic products in China. The group mainly distributes in vitro diagnostic products in Beijing, Shanghai, Guangzhou, Shenzhen and other cities, Anhui, Fujian, Guangdong, Hainan, Hunan, Jiangsu and Hebei provinces, Guangxi, Inner Mongolia and other autonomous regions.
Getein Biotech Inc(603387) said that after the completion of this transaction, the company can form synergy and complementarity with the existing distribution and marketing platform of the target company, which will effectively enrich the resources of the company's medical institutions, strengthen the penetration of high-grade hospitals, further strengthen the construction of the company's own channels, promote the expansion of markets outside China, ensure the sales of self-produced products, lay a good foundation for the company's further development in the field of IVD and extend its strategic layout, Better promote the future development of the company.
bottom copy? Target company's revenue of 4.9 billion
only 2.2 billion market value
reporters noted that the stock price of superstar medical holdings is about 1 yuan per share, which has almost become a "fairy stock" (a stock with a price of less than HK $1 per share)
In 2021, the revenue of superstar medical was 4.931 billion yuan, and the net profit attributable to the parent was 3.327 million yuan. As of press time, the total market value of superstar medical was HK $2.658 billion, about 2.260 billion yuan.
Superstar medical financial indicators
Getein Biotech Inc(603387) 2021 revenue was 1.372 billion yuan, less than one third of that of superstar medical, but the net profit attributable to parent company of 392 million yuan was significantly ahead of superstar medical. As of press time, Getein Biotech Inc(603387) market value is 7.244 billion yuan.
both parties will develop in coordination
Superstar biology is one of the largest distributors of Roche diagnostic medical in vitro diagnostic products in China. It has established a huge sales network in China, a wide range of hospitals, a perfect distribution platform of medical institutions at all levels and an excellent operation and management team.
The reporter noted that the official website of superstar medical has such a sentence: "superstar medical will continue to look for potential M & A opportunities and establish strategic partnerships with industry giants to consolidate its strong position in the medical industry." However, the one acquired this time has become himself.
For this potential transaction, star medical said that Getein Biotech Inc(603387) is introduced as a strategic investor this time, and its R & D ability can produce synergy with the company's existing business, which is conducive to the company's development of in vitro diagnostic products, cooperate with the company's transformation into a comprehensive solution supplier and expand the international market.
